HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 2, 2011, Pages 61-69

  Zhuang, Luning ^a,b,c   Gao, Jing ^b   Zeng, Yong ^b   Yu, Fei ^a   Zhang, Bingjie ^d   Li, Mu ^d   Derendorf, Hartmut ^c   Liu, Changxiao ^b  

^a TIANJIN UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

HPLC UV; Lomustine; NONMEM; Population pharmacokinetic model; Thermosensitive liposome

Indexed keywords

LOMUSTINE; MONOMERIC NONIONIC CONTRAST MEDIUM; THERMOSENSITIVE LIPOSOME ENCAPSULATED LOMUSTINE CONTAINING IOHEXOL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DRUG CARRIER; IOHEXOL; LIPOSOME;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG ISOLATION; DRUG SOLUTION; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; RELIABILITY; ULTRAVIOLET SPECTROSCOPY; VALIDATION STUDY; ANIMAL; BRAIN TUMOR; DRUG FORMULATION; INTRAVENOUS DRUG ADMINISTRATION; QUALITY CONTROL; RADIOGRAPHY; REPRODUCIBILITY; STATISTICAL MODEL; TUMOR CELL LINE; ULTRAVIOLET SPECTROPHOTOMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BRAIN NEOPLASMS; CALIBRATION; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; DRUG CARRIERS; DRUG COMPOUNDING; GLIOMA; INJECTIONS, INTRAVENOUS; IOHEXOL; LIPOSOMES; LOMUSTINE; MODELS, STATISTICAL; QUALITY CONTROL; RATS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80052521184     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0030-4     Document Type: Article

References (24)

1. Bethune CR, Geyer RJ, Spence AM, Ho RJ (2001) Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)- 3-cyclohexyl-1- nitrosourea] to suppress 36B-10 tumor growth in rats. Cancer Res 61(9):3669-3674. (Pubitemid 32694978)
2. Borel AG, Abbott FS (1993) Identification of carbamoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)- 3-cyclohexyl-1-nitrosourea, in rats and humans. Drug Metab Dispos 21(5):889-901. (Pubitemid 23298457)
3. Carter SK, Schabel FM Jr, Broder LE, Johnston TP (1972) 1, 3-Bis(2- chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res 16:273-332.
4. Cavalier E, Rozet E, Dubois N, Charlier C, Hubert P, Chapelle JP, Krzesinski JM, Delanaye P (2008) Performance of iohexol determination in serum and urine by HPLC: validation, risk and uncertainty assessment. Clin Chim Acta 396(1-2):80-85.
5. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691-743.
6. Elrod DB, Partha R, Danila D, Casscells SW, Conyers JL (2009) An iodinated liposomal computed tomographic contrast agent prepared from a diiodophosphatidylcholine lipid. Nanomedicine 5(1):42-45.
7. El-Yazigi A, Martin CR (1988) Capillary gas chromatography and thermionic N-P-specific detection of 1, 3-bis(2-chloroethyl)- 1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl- 1-nitrosourea (CCNU) in stability and pharmacokinetic studies. Pharm Res 5(4):220-225.
8. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV (2003) Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43(6):610-623. (Pubitemid 36613120)
9. FDA (1999) Guidance for industry on Population Pharmacokinetics; availability. Food and Drug Administration, HHS. Notice. Fed Regist 64(27):6663-6664.
10. Geldof M, Freijer J, van Beijsterveldt L, Timmerman P, Ahnaou A, Drinkenburg WH, Danhof M (2007) Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. Eur J Pharm Sci 30(1):45-55. (Pubitemid 44908926)
11. Iwi G, Millard RK, Palmer AM, Preece AW, Saunders M (1999) Bootstrap resampling: a powerful method of assessing confidence intervals for doses from experimental data. Phys Med Biol 44(4):N55-N62. (Pubitemid 29185395)
12. Kao CY, Hoffman EA, Beck KC, Bellamkonda RV, Annapragada AV (2003) Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol 10(5):475-483. (Pubitemid 36534888)
13. Kastrissios H, Chao NJ, Blaschke TF (1996) Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. Cancer Chemother Pharmacol 38(5):425-430. (Pubitemid 26281079)
14. Lukyanov AN, Torchilin VP (2004) Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 56(9):1273-1289. (Pubitemid 38510474)
15. Mukundan S Jr, Ghaghada KB, Badea CT, Kao CY, Hedlund LW, Provenzale JM, Johnson GA, Chen E, Bellamkonda RV, Annapragada A (2006) A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol 186(2):300-307. (Pubitemid 46100296)
16. Nagahiro S, Yamamoto YL, Diksic M, Mitsuka S, Sugimoto S, Feindel W (1991) Neurotoxicity after intracarotid 1, 3-bis(2-chloroethyl)- 1-nitrosourea administration in the rat: hemodynamic changes studied by double-tracer autoradiography. Neurosurgery 29(1): 19-25 (discussion 26).
17. Sarashina A, Tatami S, Yamamura N, Tsuda Y, Igarashi T (2005) Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. Br J Clin Pharmacol 59(1):43-53. (Pubitemid 40040095)
18. Shen Y (2007) Preparation of lomustine liposomes and its pharmacokinetics in rats. Chin Pharm J 42(1):7.
19. Sponzo RW, DeVita VT, Oliverio VT (1973) Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4- methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man. Cancer 31(5):1154-1156.
20. Vachek J, Svatek E, Kakac B (1982) Spectrophotometric and polarographic determination of lomustine. Cesk Farm 31(9):351-352.
21. Wong KH, Wallen CA, Wheeler KT (1990) Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. Int J Radiat Oncol Biol Phys 18(5):1043-1050. (Pubitemid 20182336)
22. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R (1978) Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202(4374):1290-1293. (Pubitemid 9154441)
23. Zamboni WC (2005) Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 11(23):8230-8234. (Pubitemid 41746931)
24. Zheng J, Liu J, Dunne M, Jaffray DA, Allen C (2007) In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 24(6):1193- 1201. (Pubitemid 46798881)